Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Contineum TherapeuticsCTNM -1.37%17 EBIT per Share is $-2.00 as of Jun. 2026. GuruFocus rates CTNM with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 1,172 Biotechnology companies, Contineum Therapeutics ranks worse than 88.4% on this metric.
Contineum Therapeutics's EBIT per Share for the
three
months ended in Jun. 2026 was $-0.47.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $-2.00.
During the past 3 years, the average EBIT per Share Growth Rate was -24.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Contineum Therapeutics's EBIT per Share or its related term are showing as below:
CTNM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -24.3 Med: -21 Max: -17.7
Current: -24.3
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Contineum Therapeutics was -17.70% per year. The lowest was -24.30% per year. And the median was -21.00% per year.
CTNM's 3-Year EBIT Growth Rate is ranked worse than 88.4% of 1172
companies
in the Biotechnology industry
Industry Median: 15.5
vs CTNM: -24.30
Contineum Therapeutics (NAS:CTNM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Contineum Therapeutics EBIT per Share Related Terms
Contineum Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Contineum Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Contineum Therapeutics (CTNM) has a EBIT per Share of $-2.00 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Contineum Therapeutics and its competitors. According to the industry distribution chart, Contineum Therapeutics ranks #1036 out of 1172 companies in the Biotechnology industry, placing it in the top 88.4%.
Is Contineum Therapeutics' EBIT per Share too high?
Contineum Therapeutics' current EBIT per Share is $-2.00. Based on the distribution chart, Contineum Therapeutics ranks #1036 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Contineum Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Contineum Therapeutics' EBIT per Share compare to FDMT and PRME?
According to the Biotechnology industry distribution chart, Contineum Therapeutics ranks #1036 out of 1172 companies for EBIT per Share. This places Contineum Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Contineum Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Contineum Therapeutics's current EBIT per Share is $-2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Contineum Therapeutics stock overvalued right now?
Contineum Therapeutics (CTNM) has a current EBIT per Share of $-2.00. The current EBIT per Share is $-2.00. Contineum Therapeutics' overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Contineum Therapeutics (CTNM), the current EBIT per Share is $-2.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
17GF Score
Get the complete analysis for CTNM
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTNM has been successfully added to your 
